Protocol Ledger

NCT07028853 · Phase III · RECRUITING

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

Interventional Phase III clinical trial protocol NCT07028853 sponsored by Pfizer in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-09-28 Enrollment: 1,000 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07028853
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)1,000 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07028853
Protocol FieldVerified Registry Value
NCT IdentifierNCT07028853
Consolidated Lead SponsorPfizer
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment1,000 participants (ESTIMATED)
Registered Start Date2025-09-28
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07028853
Hospital Research SiteLocationSite Profile
Cedars-Sinai Medical CenterLos Angeles, CAOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI